Snehal Naik

1.6k total citations
40 papers, 1.3k citations indexed

About

Snehal Naik is a scholar working on Genetics, Surgery and Molecular Biology. According to data from OpenAlex, Snehal Naik has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 16 papers in Surgery and 15 papers in Molecular Biology. Recurrent topics in Snehal Naik's work include Inflammatory Bowel Disease (22 papers), Microscopic Colitis (10 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Snehal Naik is often cited by papers focused on Inflammatory Bowel Disease (22 papers), Microscopic Colitis (10 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Snehal Naik collaborates with scholars based in United States, France and Spain. Snehal Naik's co-authors include David Piwnica‐Worms, Colin H. Macphee, Daniel J. Rader, Jeffrey T. Billheimer, George H. Rothblat, Víctor M. Villalobos, Xun Wang, Michael Jaye, Da Silva and Muredach P. Reilly and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Snehal Naik

38 papers receiving 1.3k citations

Peers

Countries citing papers authored by Snehal Naik

Since Specialization

Citations

This map shows the geographic impact of Snehal Naik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Snehal Naik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Snehal Naik more than expected).

Fields of papers citing papers by Snehal Naik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Snehal Naik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Snehal Naik. The network helps show where Snehal Naik may publish in the future.

Co-authorship network of co-authors of Snehal Naik

This figure shows the co-authorship network connecting the top 25 collaborators of Snehal Naik. A scholar is included among the top collaborators of Snehal Naik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Snehal Naik. Snehal Naik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial 2025 ·The Lancet. Gastroenterology & hepatology ·(unknown), (unknown), Geert D’Haens, Stefan Schreiber, Vipul Jairath, (unknown), Jarosław Kierkuś, Mieczysław Walczak, Snehal Naik, Kye Gilder, (unknown), Kathleen M. Ogilvie, William J. Sandborn, Séverine Vermeire, David T. Rubin, Laurent Peyrin‐Biroulet, Silvio Danese	4
2	P1001 Efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 trial 2025 ·Journal of Crohn s and Colitis ·Silvio Danese, Vipul Jairath, Bruce E. Sands, S Schreiber, (unknown), Geert D’Haens, (unknown), Ken Liu, William J. Sandborn, David T. Rubin, Laurent Peyrin‐Biroulet, Séverine Vermeire, Snehal Naik	1
3	987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL 2024 ·Gastroenterology ·Bruce E. Sands, (unknown), Geert D’Haens, Stefan Schreiber, (unknown), Jarosław Kierkuś, Snehal Naik, Kye Gilder, Chohee Yun, William J. Sandborn, (unknown), Séverine Vermeire, David T. Rubin, Laurent Peyrin‐Biroulet, Silvio Danese	0
4	OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial 2024 ·Journal of Crohn s and Colitis ·B E Sands, Remo Panaccione, Geert D’Haens, Stefan Schreiber, (unknown), Jarosław Kierkuś, Snehal Naik, Kye Gilder, Chohee Yun, W. Sandborn, Mieczysław Walczak, Séverine Vermeire, David T. Rubin, Laurent Peyrin‐Biroulet, Silvio Danese	5
5	43073 Pharmacokinetics, Safety and Pharmacodynamics of VTX2735, A Potent and Selective NLRP3 Inhibitor, In Healthy Adult Volunteers 2023 ·Journal of the American Academy of Dermatology ·William J. Sandborn, (unknown), Kathleen M. Ogilvie, Fei Liu, Snehal Naik, (unknown), Shendong Yuan, John M. Nuss	2
6	P209 Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis 2022 ·Poster presentations ·(unknown), Michael Chiorean, Séverine Vermeire, Julián Panés, Laurent Peyrin‐Biroulet, Bruce E. Sands, (unknown), Snehal Naik, (unknown), (unknown), William J. Sandborn	1
7	Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases 2019 ·Digestive Diseases and Sciences ·Andrés Yarur, (unknown), Snehal Naik, Poonam Beniwal‐Patel, Caroline S. Fox, Anjali Jain, (unknown), Amir Patel, Ryan C. Ungaro, (unknown), Marla Dubinsky, Dan J. Stein	36
8	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis 2019 ·Gastroenterology ·William J. Sandborn, Laurent Peyrin‐Biroulet, Jinkun Zhang, Michael Chiorean, Séverine Vermeire, Scott D. Lee, Tanja Kühbacher, Bruce Yacyshyn, Christopher H. Cabell, Snehal Naik, Preston Klassen, Julián Panés	175
9	764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study 2019 ·The American Journal of Gastroenterology ·Michael Chiorean, Séverine Vermeire, Julián Panés, Laurent Peyrin‐Biroulet, Jinkun Zhang, Bruce E. Sands, (unknown), C. H. Cabell, Snehal Naik, Preston Klassen, William J. Sandborn	2
10	PD-006 Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy 2017 ·Inflammatory Bowel Diseases ·Ryan C. Ungaro, Jacqueline Jossen, Becky L. Phan, (unknown), Anjali Jain, Snehal Naik, Marla C. Dubinsky	3
11	Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay 2017 ·Current Medical Research and Opinion ·David T. Rubin, Snehal Naik, Venkateswarlu Kondragunta, (unknown), Anjali Jain	4
12	The functional repertoire of rabbit antibodies and antibody discovery via next-generation sequencing 2014 ·mAbs ·Sreekumar Kodangattil, Christine Huard, (unknown), (unknown), (unknown), Alessandro Mascioni, Santosh Hodawadekar, Snehal Naik, (unknown), Alberto Visintin, Juan C. Almagro	21
13	Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment 2011 ·Translational Psychiatry ·Xiaolan Hu, Eve H. Pickering, Sara Hall, Snehal Naik, (unknown), Holly Soares, Elyse Katz, Sara A. Paciga, (unknown), Paul Aisen, Kelly R. Bales, Tarek A. Samad, (unknown), (unknown)	30
14	Establishment of paternal allele-specific DNA methylation at the imprinted mouseGtl2locus 2011 ·Epigenetics ·(unknown), Geneva M. Stein, (unknown), (unknown), Snehal Naik, J. Morris, Sara Marlow, Tamara L. Davis	27
15	PPARγ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI 2011 ·Biochemical Pharmacology ·Sue‐Anne Toh, John S. Millar, Jeffrey T. Billheimer, Ilia V. Fuki, Snehal Naik, Colin H. Macphee, Max Walker, Daniel J. Rader	17
16	Dual-Color Click Beetle Luciferase Heteroprotein Fragment Complementation Assays 2010 ·Chemistry & Biology ·Víctor M. Villalobos, Snehal Naik, Monique W. Bruinsma, Robin S. Dothager, (unknown), Mustapha M. Samrakandi, Britney L. Moss, Adnan Elhammali, David Piwnica‐Worms	61
17	Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer 2009 ·Clinical Cancer Research ·Snehal Naik, Robin S. Dothager, Jayne Marasa, (unknown), David Piwnica‐Worms	58
18	Both the Peroxisome Proliferator‐Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL‐Derived Cholesterol 2009 ·Clinical and Translational Science ·François Briand, Snehal Naik, Ilia V. Fuki, John S. Millar, Colin H. Macphee, Max Walker, Jeffrey T. Billheimer, George H. Rothblat, Daniel J. Rader	63
19	Regulation of Cysteinyl Leukotriene Type 1 Receptor Internalization and Signaling 2004 ·Journal of Biological Chemistry ·Snehal Naik, Charlotte K. Billington, Rodolfo M. Pascual, Deepak A. Deshpande, Frank P. Stefano, Trudy A. Kohout, Delrae M. Eckman, Jeffrey Benovic, Raymond B. Penn	53
20	Does Entamoeba histolytica cause irritable bowel syndrome? 1997 ·PubMed ·(unknown), UC Ghoshal, G. Choudhuri, Snehal Naik, (unknown), (unknown)	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact